MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Atvērts

3.14 0.32

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.96

Max

3.16

Galvenie mērījumi

By Trading Economics

Ienākumi

-17M

-70M

Pārdošana

547K

47M

Peļņas marža

-147.345

Darbinieki

560

EBITDA

-17M

-66M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+48.73% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

280M

1B

Iepriekšējā atvēršanas cena

2.82

Iepriekšējā slēgšanas cena

3.14

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 2. okt. 23:30 UTC

Karstas akcijas

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2025. g. 2. okt. 21:21 UTC

Peļņas

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

2025. g. 3. okt. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2025. g. 2. okt. 23:40 UTC

Tirgus saruna

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2025. g. 2. okt. 23:39 UTC

Tirgus saruna

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2025. g. 2. okt. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2025. g. 2. okt. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2025. g. 2. okt. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2025. g. 2. okt. 23:00 UTC

Tirgus saruna

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2025. g. 2. okt. 22:54 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Scales's JV Buyout Lauded by Bull -- Market Talk

2025. g. 2. okt. 22:54 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. okt. 22:46 UTC

Tirgus saruna

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2025. g. 2. okt. 22:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. okt. 21:17 UTC

Iegādes, apvienošanās, pārņemšana

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2025. g. 2. okt. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Energy & Utilities Roundup: Market Talk

2025. g. 2. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 2. okt. 20:49 UTC

Iegādes, apvienošanās, pārņemšana

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2025. g. 2. okt. 20:00 UTC

Iegādes, apvienošanās, pārņemšana

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2025. g. 2. okt. 19:20 UTC

Tirgus saruna

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2025. g. 2. okt. 19:10 UTC

Tirgus saruna

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2025. g. 2. okt. 19:04 UTC

Tirgus saruna

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2025. g. 2. okt. 18:46 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2025. g. 2. okt. 18:46 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2025. g. 2. okt. 18:46 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2025. g. 2. okt. 18:45 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2025. g. 2. okt. 18:45 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2025. g. 2. okt. 18:44 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2025. g. 2. okt. 18:44 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2025. g. 2. okt. 18:44 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2025. g. 2. okt. 18:43 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Salīdzinājums

Cenas izmaiņa

Maravai LifeSciences Holdings Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

48.73% augšup

Prognoze 12 mēnešiem

Vidējais 4.67 USD  48.73%

Augstākais 5 USD

Zemākais 4 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Maravai LifeSciences Holdings Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

4

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

2.02 / 2.115Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

No Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat